Kazia Therapeutics Files 2024 Annual Report
Ticker: KZIA · Form: 6-K · Filed: Mar 13, 2025 · CIK: 1075880
Sentiment: neutral
Topics: annual-report, filing
TL;DR
Kazia Therapeutics dropped its 2024 annual report on 3/11/25.
AI Summary
Kazia Therapeutics Limited filed its Annual Report to shareholders for the fiscal year ended June 30, 2024, on March 11, 2025. The report is attached as Exhibit 99.1 to this Form 6-K filing.
Why It Matters
This filing provides shareholders with a comprehensive overview of the company's performance and financial standing for the past fiscal year.
Risk Assessment
Risk Level: low — This is a routine annual report filing and does not contain new material financial or operational information that would significantly alter risk.
Key Players & Entities
- Kazia Therapeutics Limited (company) — Registrant
- June 30, 2024 (date) — Fiscal Year End
- March 11, 2025 (date) — Filing Date of Annual Report
- Exhibit 99.1 (document) — Attached Annual Report
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report that Kazia Therapeutics Limited provided its Annual Report to shareholders for the fiscal year ended June 30, 2024, on March 11, 2025.
When was Kazia Therapeutics Limited's fiscal year end?
Kazia Therapeutics Limited's fiscal year ended on June 30, 2024.
On what date was the Annual Report provided to shareholders?
The Annual Report was provided to shareholders on March 11, 2025.
Which exhibit contains the Annual Report?
The Annual Report is attached as Exhibit 99.1 to this Form 6-K filing.
What is the company's principal executive office address?
The company's principal executive office is located at Three International Towers Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 13, 2025 regarding KAZIA THERAPEUTICS LTD (KZIA).